Portal de Periódicos da CAPES

Aplastic Anemia: First-line Treatment by Immunosuppression and Sibling Marrow Transplantation

2010; American Society of Hematology; Volume: 2010; Issue: 1 Linguagem: Inglês

10.1182/asheducation-2010.1.36

1520-4391

Jakob Passweg, Judith Marsh,

Mesenchymal stem cell research

Abstract Newly diagnosed aplastic anemia is a serious condition, with more than 75% (higher in young patients) becoming long-term survivors if diagnosed and treated appropriately. First-line treatment approaches include immunosuppressive treatment using the combination of antithymocyte globulin and cyclosporine A for patients without a sibling donor and HLA identical sibling transplant for patients younger than age 40 with a donor. Best transplant strategies have been defined and include conditioning with cyclophosphamide and antithymocyte globulin, marrow as a stem cell source, and graft-versus-host diease prophylaxis using cyclosporine A and methotrexate. It is against these standard treatment approaches that any therapeutic progress has to be measured.